Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery

Scott M. Wentz, Francis Price, Alon Harris, Brent Siesky, Thomas Ciulla

Research output: Contribution to journalArticle

Abstract

Introduction: Bromfenac is a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) used to reduce pain and treat post-operative inflammation after cataract surgery. Bromfenac 0.075% in the DuraSite™ vehicle is a newly-approved formulation which has been shown to be efficacious and safe for use in cataract surgery to reduce pain and treat inflammation. It has been shown to have a slightly better posterior segment ocular bioavailability compared to similar topical ophthalmic NSAIDs. However, there is a paucity of studies investigating its role in the prevention and treatment of post-operative pseudophakic cystoid macular edema. Areas covered: In this review, the authors provide an overview of similar products available, describe the novelty of bromfenac 0.075% in the DuraSite vehicle, and discuss the relevant clinical studies to determine if the formulation is safe and efficacious. Expert opinion: Bromfenac 0.075% in the DuraSite vehicle is a new topical ophthalmic medication which has been approved by the FDA for the prevention of pain and treatment of post-operative inflammation. It provides cataract surgeons with an additional medication for cataract surgery. However, no robust studies have been performed showing the effect that it has on the reduction or prevention of post-operative pseudophakic cystoid macular edema.

Original languageEnglish (US)
Pages (from-to)1703-1709
Number of pages7
JournalExpert opinion on pharmacotherapy
Volume20
Issue number14
DOIs
StatePublished - Oct 1 2019

Fingerprint

Cataract
Inflammation
Safety
Pain
Macular Edema
Expert Testimony
Non-Steroidal Anti-Inflammatory Agents
Biological Availability
Anti-Inflammatory Agents
bromfenac
Therapeutics
Pharmaceutical Preparations

Keywords

  • bromfenac
  • cataract
  • CME
  • CMO
  • drug
  • DuraSite
  • NSAID
  • Ophthalmology
  • optometry
  • pharmaceuticals

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery. / Wentz, Scott M.; Price, Francis; Harris, Alon; Siesky, Brent; Ciulla, Thomas.

In: Expert opinion on pharmacotherapy, Vol. 20, No. 14, 01.10.2019, p. 1703-1709.

Research output: Contribution to journalArticle

@article{829909209f7a446bac6a2862d218e8fd,
title = "Efficacy and safety of bromfenac 0.075{\%} formulated in DuraSite for pain and inflammation in cataract surgery",
abstract = "Introduction: Bromfenac is a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) used to reduce pain and treat post-operative inflammation after cataract surgery. Bromfenac 0.075{\%} in the DuraSite™ vehicle is a newly-approved formulation which has been shown to be efficacious and safe for use in cataract surgery to reduce pain and treat inflammation. It has been shown to have a slightly better posterior segment ocular bioavailability compared to similar topical ophthalmic NSAIDs. However, there is a paucity of studies investigating its role in the prevention and treatment of post-operative pseudophakic cystoid macular edema. Areas covered: In this review, the authors provide an overview of similar products available, describe the novelty of bromfenac 0.075{\%} in the DuraSite vehicle, and discuss the relevant clinical studies to determine if the formulation is safe and efficacious. Expert opinion: Bromfenac 0.075{\%} in the DuraSite vehicle is a new topical ophthalmic medication which has been approved by the FDA for the prevention of pain and treatment of post-operative inflammation. It provides cataract surgeons with an additional medication for cataract surgery. However, no robust studies have been performed showing the effect that it has on the reduction or prevention of post-operative pseudophakic cystoid macular edema.",
keywords = "bromfenac, cataract, CME, CMO, drug, DuraSite, NSAID, Ophthalmology, optometry, pharmaceuticals",
author = "Wentz, {Scott M.} and Francis Price and Alon Harris and Brent Siesky and Thomas Ciulla",
year = "2019",
month = "10",
day = "1",
doi = "10.1080/14656566.2019.1645834",
language = "English (US)",
volume = "20",
pages = "1703--1709",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "14",

}

TY - JOUR

T1 - Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery

AU - Wentz, Scott M.

AU - Price, Francis

AU - Harris, Alon

AU - Siesky, Brent

AU - Ciulla, Thomas

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Introduction: Bromfenac is a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) used to reduce pain and treat post-operative inflammation after cataract surgery. Bromfenac 0.075% in the DuraSite™ vehicle is a newly-approved formulation which has been shown to be efficacious and safe for use in cataract surgery to reduce pain and treat inflammation. It has been shown to have a slightly better posterior segment ocular bioavailability compared to similar topical ophthalmic NSAIDs. However, there is a paucity of studies investigating its role in the prevention and treatment of post-operative pseudophakic cystoid macular edema. Areas covered: In this review, the authors provide an overview of similar products available, describe the novelty of bromfenac 0.075% in the DuraSite vehicle, and discuss the relevant clinical studies to determine if the formulation is safe and efficacious. Expert opinion: Bromfenac 0.075% in the DuraSite vehicle is a new topical ophthalmic medication which has been approved by the FDA for the prevention of pain and treatment of post-operative inflammation. It provides cataract surgeons with an additional medication for cataract surgery. However, no robust studies have been performed showing the effect that it has on the reduction or prevention of post-operative pseudophakic cystoid macular edema.

AB - Introduction: Bromfenac is a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) used to reduce pain and treat post-operative inflammation after cataract surgery. Bromfenac 0.075% in the DuraSite™ vehicle is a newly-approved formulation which has been shown to be efficacious and safe for use in cataract surgery to reduce pain and treat inflammation. It has been shown to have a slightly better posterior segment ocular bioavailability compared to similar topical ophthalmic NSAIDs. However, there is a paucity of studies investigating its role in the prevention and treatment of post-operative pseudophakic cystoid macular edema. Areas covered: In this review, the authors provide an overview of similar products available, describe the novelty of bromfenac 0.075% in the DuraSite vehicle, and discuss the relevant clinical studies to determine if the formulation is safe and efficacious. Expert opinion: Bromfenac 0.075% in the DuraSite vehicle is a new topical ophthalmic medication which has been approved by the FDA for the prevention of pain and treatment of post-operative inflammation. It provides cataract surgeons with an additional medication for cataract surgery. However, no robust studies have been performed showing the effect that it has on the reduction or prevention of post-operative pseudophakic cystoid macular edema.

KW - bromfenac

KW - cataract

KW - CME

KW - CMO

KW - drug

KW - DuraSite

KW - NSAID

KW - Ophthalmology

KW - optometry

KW - pharmaceuticals

UR - http://www.scopus.com/inward/record.url?scp=85072546492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072546492&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1645834

DO - 10.1080/14656566.2019.1645834

M3 - Article

C2 - 31343372

AN - SCOPUS:85072546492

VL - 20

SP - 1703

EP - 1709

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 14

ER -